Effective July 1, 2025, Medicare Will Transition FQHC Part B Preventive Vaccine Reimbursement from Cost Report-Based to Claim-Based
Federally Qualified Health Centers (FQHCs) are facing a major change in how they bill Medicare for preventive vaccines. Starting July 1, 2025, the reimbursement process will shift from cost-report-based payments to claim-based billing under Medicare Part B. This transition represents a significant operational and financial shift for FQHC executives, requiring new billing workflows, system updates, and staff training.
Key Changes at a Glance
- Vaccine/toxoids and their administrations will be billed on an institutional claim (UB-04) using standard HCPCS/CPT codes.
- No qualifying visit is required—vaccines will not be included in the all-inclusive rate (AIR) or Prospective Payment System (PPS) reimbursement.
- Reimbursement will be separate under Medicare Part B, shifting from the traditional cost report model.
- COVID-19 vaccines will have Medicare-determined rates, while other vaccines will be reimbursed at 95% of the Average Wholesale Price (AWP).
- M0201 may be billed for additional payment when vaccine(s) are administered in the home and all CMS RHC/FQHC and in-home payment guidelines are met.
Billing Requirements & Codes
FQHC vaccine/toxoid and administration services must be billed separately on claims using the following HCPCS/CPT codes:
Vaccine Product Codes & Reimbursement
|
Vaccine Type
|
HCPCS/CPT Codes
|
Reimbursement Method
|
|
Influenza Vaccine
|
90630, 90653, 90654, etc.
|
95% of AWP
|
|
Pneumococcal Vaccine
|
90670, 90732
|
95% of AWP
|
|
Hepatitis B Vaccine
|
90739, 90740, 90746, etc.
|
95% of AWP
|
|
COVID-19 Vaccine
|
Varies by brand
|
Medicare-determined rate
|
Vaccine Administration Codes
|
Administration Code
|
Description
|
|
G0008
|
Influenza vaccine administration
|
|
G0009
|
Pneumococcal vaccine administration
|
|
G0010
|
Hepatitis B vaccine administration
|
|
COVID-19 Codes
|
Vary by dose and vaccine type
|
|
90480
|
COVID-19 administration
|
|
M0201
|
Preventive Vaccine Home Administration
|
What This Means for FQHC Executives
This transition requires careful planning to avoid reimbursement delays and compliance risks. FQHC leaders must ensure their teams are prepared for claim-based billing and update internal systems accordingly. Key areas to address:
-
Electronic Health Record (EHR) & Billing System Updates
-
Staff Training & Compliance
- Educate billing teams on the shift from cost-report-based to claim-based vaccine billing.
- Train staff to properly submit UB-04 claims with the appropriate vaccine and administration codes.
-
Financial Impact Analysis
- The change may impact FQHC revenue streams. Conduct a financial review to model how this shift will affect vaccine-related reimbursement.
- Monitor Medicare updates on COVID-19 vaccine payment rates to avoid revenue disruptions.
How Synergy Billing Can Help
Navigating these changes can be complex, but Synergy Billing is here to support FQHCs through this transition. Our team of experts is prepared to help ensure that your billing systems, workflows, and teams are ready for the shift to claim-based reimbursement.
We offer a
free 'Ask the Expert' resource where FQHC executives and billing teams can get personalized guidance on how to implement these changes. If you have any questions about setting up your system or properly billing for vaccines, contact
Synergy Billing’s 'Ask the Expert' service today.
📩 Get Expert Help – Reach out to us at 877-242-8475 or request help below to ensure a smooth transition before July 1, 2025.
Stay ahead of the changes and make sure your FQHC is prepared for Medicare’s new vaccine billing requirements!